Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 1: Phase 3 study of AZD6234 in adults with obesity or overweight with weight-related comorbidities and without type 2 diabetes
CTR20263937Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lenbelintide in obesity, Overweight, sponsored by AstraZeneca. Started Sep 2026; status: active.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20263937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263937.